In ten years, obesity pharmacology has gone from "a few percentage points of weight loss" to "the most effective metabolic intervention ever made available." Here is the complete map — what is approved, what is filed, what is in trials, and how to think about which generation you are using.
The simplest way to keep this field straight is by generation — defined by how many receptors a single molecule activates. Each new generation has produced more weight loss than the last:
Ozempic (T2D), Wegovy (obesity), Rybelsus (oral, T2D). Same molecule, different brand names and indications. The drug that made GLP-1 a household word. Phase 3 STEP program produced ~14.9% mean weight loss at 68 weeks. The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease — a uniquely strong evidence base that no other GLP-1 has yet matched.
Where semaglutide still wins in 2026: cardiovascular protection, oral formulation availability (Rybelsus), and lower cost in some payer scenarios. Where it loses: weight-loss efficacy versus tirzepatide.
Mounjaro (T2D), Zepbound (obesity, OSA). Adding the GIP receptor delivered ~22.5% mean weight loss in SURMOUNT-1 — and SURMOUNT-5 (NEJM 2025) confirmed superiority versus semaglutide head-to-head (20.2% vs. 13.7%). Tirzepatide also has the cleaner GI tolerability profile because GIP agonism modulates the nausea pathway.
In 2024, tirzepatide was added to the FDA's approved indication list for obstructive sleep apnea in adults with obesity — the first GLP-1/GIP to reach that indication. The cardiovascular outcomes trial SURPASS-CVOT is pending but expected to show CV benefit similar to (though not yet proven equal to) semaglutide.
The first triple agonist to reach Phase 3. TRIUMPH-4 (December 2025) produced 28.7% mean weight loss at the 12 mg dose over 68 weeks — the highest figure ever reported in a Phase 3 obesity trial. Adding the glucagon receptor turns up resting energy expenditure and lipolysis, which is what allows the additional weight loss.
Seven additional Phase 3 readouts are expected through 2026, including TRIUMPH-1 (the largest registration trial), TRIUMPH-2, and the cardiovascular outcomes trial. NDA submission is anticipated late 2026 with FDA approval likely in late 2027 or early 2028. Retatrutide is investigational as of May 2026 and is not legally compoundable in the U.S.
For the deep dive, read our Retatrutide 2026 article covering the Phase 3 program, mechanism, and FDA timeline.
Generation 4 is less about adding receptors and more about (a) different mechanisms, (b) different delivery formats, and (c) the maturation of the field beyond "more weight loss is always better."
Novo Nordisk's combination of semaglutide and cagrilintide (a long-acting amylin analog). Filed for FDA approval in December 2025, PDUFA date around October 2026 — making CagriSema the most likely new obesity drug to reach the market in 2026. Phase 3 REDEFINE results showed weight loss between semaglutide alone and tirzepatide alone, with potentially smoother appetite suppression because amylin and GLP-1 hit different satiety pathways.
Eli Lilly's oral, non-peptide GLP-1. ATTAIN-1 (completed August 2025) showed 12.4% mean weight loss at 72 weeks. Significantly less weight loss than injectable competitors, but the format advantage is real: orforglipron is an oral pill that does not require the food/water timing restrictions that Rybelsus does. NDA filing anticipated in 2026.
For patients who refuse injections, orforglipron will be the first true oral option in this category.
Boehringer Ingelheim's GLP-1/glucagon dual agonist (notably without GIP). Phase 2 produced ~19% weight loss; Phase 3 SYNCHRONIZE program is ongoing with no efficacy readouts yet. The mechanistic interest is high because survodutide is studying whether you can replicate retatrutide-class weight loss without GIP — relevant if any GIP-related safety signal emerges in the broader class.
| Drug | Mechanism | Phase 3 weight loss | FDA status |
|---|---|---|---|
| Semaglutide | GLP-1 | ~14.9% | Approved |
| Tirzepatide | GLP-1 + GIP | ~22.5% | Approved |
| CagriSema | GLP-1 + amylin | ~22.7% | Filed · PDUFA ~Oct 2026 |
| Survodutide | GLP-1 + glucagon | ~19% (Phase 2) | Phase 3 ongoing |
| Orforglipron | Oral GLP-1 (non-peptide) | ~12.4% | NDA expected 2026 |
| Retatrutide | GLP-1 + GIP + glucagon | ~28.7% | Phase 3 ongoing · NDA late 2026 |
Phase 3 figures are mean values from largest published trials; cross-trial comparisons should be interpreted with caution because populations and durations differ.
Labs, history, comorbidities, payer access, and goals all factor in. We map your decision against the full landscape — not whichever drug the loudest voice on the internet recommends.
Book a Consultation Founding Membership